Manufacturing and R&D update for COVID-19 test

Paris, France and Camberley, UK – 15 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides a manufacturing, and research and development update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/04/Novacyt-COVID-19-test-update-ENGLISH-15.4.20.pdf

Visit Page

Point sur la production et la R&D du test COVID-19

Paris, France et Camberley, Royaume-Uni – 15 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur la production, la recherche et le développement de son test d’amplification en chaîne par polymérase (PCR) pour COVID-19, mis au point par Primerdesign, la division de diagnostic moléculaire

Visit Page

Collaboration with AstraZeneca, GSK and University of Cambridge to support UK national effort to increase COVID-19 testing

Paris, France and Camberley, UK – 8 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that as part of the UK Government’s announcement of a new five pillar plan to increase testing for COVID-19, Novacyt is collaborating with AstraZeneca, GSK and the University of Cambridge to take

Visit Page